Moderate to Severe COPD Treatment

Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD.

Register Today!

Trial Information

Trial DurationUp to 36 months
Number of VisitsVariable
Lead CRCJason Collin

For additional information
on this trial contact: